Drug Trial Radar · NCT05331300
A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease
Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Jun 6, 2022
Primary completion
Nov 27, 2024
Study completion Nov 27, 2024
Sponsor
- Lead sponsor
- Lassen Therapeutics 1 PTY LTDIndustry
- Sponsor type
- Industry
- First posted
- Apr 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor that is being developed to address the fibro-inflammatory pathology of pulmonary fibrosis and TED. This study is a four-part trial consisting of Parts A, B, C and D. The primary objective of this study is to evaluate the safety and tolerability of LASN01, and the secondary objective is to evaluate the preliminary efficacy, immunogenicity, and pharmacokinetics of single and multiple doses of LASN01 in healthy participants and in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrosing interstitial lung disease (PF-ILD) or Thyroid Eye disease (TED). Please note that both the Phase 1 (single and multiple ascending dose, SAD/MAD) portion in healthy volunteers and the Phase 2a portion in patients are completed.
Conditions
- Pulmonary Fibrosis
- Thyroid Eye Disease
Interventions
LASN01Drug
Escalating single and multiple doses of LASN01
LASN01Drug
LASN01 will be administered intravenously
PlaceboDrug
Escalating doses of matching placebo
PlaceboDrug
Placebo will be administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent, treatment related, and serious adverse eventsTime frame: Day 1-Day 57 in Part A, Day 1-Day 71 in Part B, Day 1-Day 211 in Part C, Day 1-Day 365 in Part D
- Changes in concomitant medicationsTime frame: Day 1-Day 57 in Part A, Day 1-Day 71 in Part B, Day 1-Day 211 in Part C, Day 1-Day 365 in Part D
- Changes from Baseline in clinical laboratory evaluations following study drug administrationTime frame: Day 1-Day 57 in Part A, Day 1-Day 71 in Part B, Day 1-Day 211 in Part C, Day 1-Day 365 in Part D
- Changes from Baseline in vital signs following study drug administrationTime frame: Day 1-Day 57 in Part A, Day 1-Day 71 in Part B, Day 1-Day 211 in Part C, Day 1-Day 365 in Part D
- Changes from Baseline in 12-lead electrocardiogram (ECG) parameters following study drug administrationTime frame: Day 1-Day 57 in Part A, Day 1-Day 71 in Part B, Day 1-Day 211 in Part C, Day 1-Day 365 in Part D
- Changes from Baseline in physical examination (PE) results following study drug administrationTime frame: Day 1-Day 57 in Part A, Day 1-Day 71 in Part B, Day 1-Day 211 in Part C, Day 1-Day 365 in Part D
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Site AU05
Hurstville, New South Wales, Australia
Site AU03
Brisbane, Queensland, Australia
Site AU01
Melbourne, Victoria, Australia
Site HK01
Shatin, Hong Kong
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.